Evidence map›Paper›PMID 17082780›Full record

ArticleLeukemia2006

Proteomic discovery of Max as a novel interacting partner of C/EBPalpha: a Myc/Max/Mad link.

A A Zada, J A Pulikkan, D Bararia, M Geletu, A K Trivedi, M Y Balkhi, W D Hiddemann, D G Tenen, H M Behre, G Behre

Abstract read
PubMed Publisher
In one paragraph

Article in Leukemia, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Comparative proteomics in acute myeloid leukemia.Contemporary oncology (Poznan, Poland) · 2012
    Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

A A ZadaBone Marrow Transplantation Unit, State Center for Cell and Gene Therapy, Clinic Internal Medicine IV, Martin-Luther-University, Halle, Germany.
J A Pulikkan
D Bararia
M Geletu
A K Trivedi
M Y Balkhi
W D Hiddemann
D G Tenen
H M Behre
G Behre
Martin Luther University Halle-Wittenberg · DEInstitute for Protein Innovation · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The transcription factor CCAAT/enhancer binding protein a (C/EBPalpha) is important in the regulation of granulopoiesis and is disrupted in human acute myeloid leukemia. In the present study, we sought to identify novel C/EBPalpha interacting proteins in vivo through immunoprecipitation using mass spectrometry-based proteomic techniques. We identified Max, a heterodimeric partner of Myc, as one of the interacting proteins of C/EBPalpha in our screen. We confirmed the in vivo interaction of C/EBPalpha with Max and showed that this interaction involves the basic region of C/EBPalpha. Endogenous C/EBPalpha and Max, but not Myc and Max, colocalize in intranuclear structures during granulocytic differentiation of myeloid U937 cells. Max enhanced the transactivation capacity of C/EBPalpha on a minimal promoter. A chromatin immunoprecipitation assay revealed occupancy of the human C/EBPalpha promoter in vivo by Max and Myc under cellular settings and by C/EBPalpha and Max under retinoic acid induced granulocytic differentiation. Interestingly, enforced expression of Max and C/EBPalpha results in granulocytic differentiation of the human hematopoietic CD34(+) cells, as evidenced by CD11b, CD15 and granulocyte colony-stimulating factor receptor expression. Silencing of Max by short hairpin RNA in CD34(+) and U937 cells strongly reduced the differentiation-inducing potential of C/EBPalpha, indicating the importance of C/EBPalpha-Max in myeloid progenitor differentiation. Taken together, our data reveal Max as a novel co-activator of C/EBPalpha functions, thereby suggesting a possible link between C/EBPalpha and Myc-Max-Mad network.

Indexed as

LeukopoiesisProteomicsBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsCCAAT-Enhancer-Binding Protein-alphaCell DifferentiationCell Line, TumorDimerizationHematopoietic Stem CellsHumansPromoter Regions, GeneticProto-Oncogene Proteins c-mycRepressor ProteinsRNA, Small InterferingThymidine KinaseBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsCCAAT-Enhancer-Binding Protein-alphaMAX protein, humanMXD1 protein, humanMYC protein, humanProto-Oncogene Proteins c-mycRepressor ProteinsRNA, Small InterferingThymidine Kinase

Identifiers

PMID17082780
OpenAlexW2119008464

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.